The pharmacokinetics of nifurtimox in chronic renal failure

The pharmacokinetics of nifurtimox, a drug used in the treatment of Trypanosoma cruzi infections, has been studied in seven patients with chronic renal failure undergoing haemodialysis, and in seven healthy subjects. Each subject took nifurtimox 15 mg.kg-1 orally and blood samples were obtained for...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical pharmacology 1992-06, Vol.42 (6), p.671-673
Main Authors: GONZALEZ-MARTIN, G, THAMBO, S, PAULOS, C, VASQUEZ, I, PAREDES, J
Format: Article
Language:English
Subjects:
Adult
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiparasitic agents
Biological and medical sciences
Female
Humans
Kidney Failure, Chronic - metabolism
Male
Medical sciences
Metabolic Clearance Rate
Middle Aged
Nifurtimox - blood
Nifurtimox - pharmacokinetics
Pharmacology. Drug treatments
Renal Dialysis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The pharmacokinetics of nifurtimox, a drug used in the treatment of Trypanosoma cruzi infections, has been studied in seven patients with chronic renal failure undergoing haemodialysis, and in seven healthy subjects. Each subject took nifurtimox 15 mg.kg-1 orally and blood samples were obtained for 10 h after administration. Nifurtimox in serum was analyzed by HPLC. The patients with chronic renal failure had a higher Cmax than the control subjects due to a change in systemic availability. An alternative explanation would be that both the distribution volume and the clearance had changed. The mean half-life in the patients with chronic renal failure was similar to that in the healthy subjects.
ISSN:0031-6970
1432-1041
DOI:10.1007/BF00265935